Navigation Links
The Westaim Corporation update on status of short-term investments
Date:11/2/2007

CALGARY, Nov. 2 /PRNewswire-FirstCall/ - The Westaim Corporation announced today the receipt of an offer, subject to final documentation, for a credit line of $12.6 million from a major financial institution. The credit facility will be available for one year and will be secured by the equivalent value of asset-backed commercial paper (ABCP) held by the Company.

Westaim previously announced that it held $19.7 million in ABCP. In September, the Company realized proceeds of $2.8 million upon the maturity of certain of its holdings, reducing its current ABCP holdings to approximately $17 million. These securities, which met the criteria of The Westaim Corporation's investment policy at the time of purchase, have been rated R-1 (high) by DBRS Limited. However, the market for $35 billion of third-party ABCP has been frozen since mid-August and until the paper is restructured, or a market otherwise forms for this ABCP, Westaim cannot be certain of the ultimate value it will realize for its holdings.

"While Westaim currently has sufficient non-ABCP cash and liquid investments, this facility greatly improves our liquidity and provides us the flexibility we need going forward," said Drew Fitch, President and CEO of Westaim. "We will continue to closely monitor the commercial paper situation and examine the optimal use of existing resources and assets."

At June 30, 2007, Westaim had a total of $33.9 million in cash and short-term investments, excluding the cash equivalents held by its 74.8 per cent owned affiliate NUCRYST Pharmaceuticals Corp.

The Westaim Corporation's technology investments include iFire Technology Corp., which is developing a low-cost flat panel display technology, and a 74.8 per cent interest in NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX; NCS), which develops, manufactures and commercializes medical products that fight infection and inflammation based on its nanocrystalline silver technology. Westaim's common shares are listed on The Toronto Stock Exchange under the trading symbol WED.

This news release contains forward-looking statements. These statements are based on current expectations that are subject to risks and uncertainties, and Westaim can give no assurance that these expectations are correct. Various factors could cause actual results to differ materially from those projected in such statements, including but not limited to statements regarding final documentation of the credit facility, the repayment of mature securities, potential adverse consequences to Westaim in future, the sufficiency of Westaim's cash and liquid investments to continue operations, Westaim's intention to monitor the asset-backed commercial paper situation referred to in the news release, and potential steps to be taken by Westaim to ensure continued access to cash necessary to fund operations. Westaim disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise. Accordingly, readers are advised not to place undue reliance on forward-looking statements, and should not rely on this information at any date other than the date of this news release. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.


'/>"/>
SOURCE Westaim Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
2. WHO Updates Outdated Pediatric Growth Charts
3. High -tech Mitochondrial DNA Sequencing Tool Updated
4. Updated Sleep Apnea Screening Recommended for Commercial Drivers
5. Warning on Avastin Updated
6. NanoSensors Provides Update on Its Biosensor to Detect E.coli and Salmonella
7. Patient’s perception of health status helps in better recover
8. FDA debates status of decongestant drugs
9. Status of some prescription drugs
10. Low Socioeconomic Status May Lead To Mental Illness
11. Post-Menopausal Status May Cause Tooth Decay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take ... an inventor from Austin, Texas, has identified a solution. , She developed a prototype ... restricted lighting. As such, it eliminates the need to turn on a light when ...
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... , ... Apple Rehab Shelton Lakes , which specializes in the delivery ... as part of a disaster drill on October 3rd. , Apple Rehab participated with ... Manager, as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
Breaking Medicine Technology: